Overview We are a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. We are focused on developing (i) a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); (ii) a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and (iii) a treatment and/or prevention for Alzheimers or other neuroinflammatory diseases (HT-ALZ). We also have assets being developed for (i) atopic dermatiti...
Q2 FY2026 — expected 2026-09-11
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-27 | 2025-12-31 | 0001213900-26-035625 | EDGAR | 68K words |
| 2025-03-28 | 2024-12-31 | 0001013762-25-004108 | EDGAR | — |
| 2024-03-28 | 2023-12-31 | 0001213900-24-027213 | EDGAR | — |
| 2023-03-31 | 2022-12-31 | 0001213900-23-025455 | EDGAR | — |
| 2022-03-30 | 2021-12-31 | 0001213900-22-015909 | EDGAR | — |
| 2021-03-16 | 2020-12-31 | 0001213900-21-015764 | EDGAR | — |
| 2020-03-02 | 2019-12-31 | 0001213900-20-005186 | EDGAR | — |
| 2019-04-01 | 2018-12-31 | 0001213900-19-005307 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-12 | 2025-09-30 | 0001213900-25-109220 | EDGAR | 27K words |
| 2025-08-12 | 2025-06-30 | 0001213900-25-074968 | EDGAR | — |
| 2025-05-12 | 2025-03-31 | 0001213900-25-042043 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0001213900-24-096778 | EDGAR | — |
| 2024-08-09 | 2024-06-30 | 0001213900-24-067131 | EDGAR | — |
| 2024-05-14 | 2024-03-31 | 0001213900-24-042906 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0001213900-23-086133 | EDGAR | — |
| 2023-08-11 | 2023-06-30 | 0001213900-23-066246 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0001213900-23-039789 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0001213900-22-071279 | EDGAR | — |
| 2022-08-12 | 2022-06-30 | 0001213900-22-047409 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0001213900-22-025987 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-04-02 | 0001213900-26-039363 | EDGAR | 23K words |
| 2026-01-16 | 0001213900-26-004899 | EDGAR | — |
| 2025-10-17 | 0001213900-25-099969 | EDGAR | — |
| 2025-09-12 | 0001213900-25-087054 | EDGAR | — |
| 2025-08-22 | 0001213900-25-079915 | EDGAR | — |
| 2025-08-05 | 0001213900-25-072068 | EDGAR | — |
| 2025-06-24 | 0001213900-25-057233 | EDGAR | — |
| 2025-06-20 | 0001213900-25-055834 | EDGAR | — |
| 2025-06-09 | 0001213900-25-052295 | EDGAR | — |
| 2025-05-16 | 0001213900-25-044894 | EDGAR | — |
150 total filings indexed. 120 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001711786 |
| Ticker | HOTH |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | NV |
| Website | https://www.hoththerapeutics.com |
| Listed | 2019-02-15 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report